Gastroenterology News

The concept of delayed gratification has been ingrained in us throughout medical school and residency. This mentality can sometimes lead to explosive spending as an attending when one enjoys a significant salary boost.

An adalimumab concentration threshold of 12.1 µg/mL “may be a target for therapeutic drug monitoring” to achieve complete fistula healing in perianal fistulizing Crohn’s disease, according to research in Clinical Gastroenterology and Hepatology.

Interim analyses of two phase 2b studies of volixibat support its use as potential treatment for patients with primary biliary cholangitis and primary sclerosing cholangitis, according to a press release from Mirum Pharmaceuticals.

The FDA granted accelerated approval adagrasib with cetuximab for the treatment of KRASG12C -mutated locally advanced or metastatic colorectal cancer, according to a press release from the agency.

The Council for Medical Specialty Societies, or CMSS, announced the launch of a new initiative that aims to reduce clinicians’ reliance on race in clinical decision-making and patient harms.

National Accreditation Program for Rectal Cancer accreditation appeared associated with better outcomes for older adults who underwent major rectal cancer surgery, according to findings in Journal of the American College of Surgeons.

Fewer ventilated patients who received pantoprazole, a widely available proton-pump inhibitor, experienced clinically important upper gastrointestinal bleeding, according to research published in the New England Journal of Medicine.

Patients with metabolic dysfunction-associated steatohepatitis and advanced fibrosis treated with tirzepatide achieved significant disease resolution without worsening of fibrosis, compared with those on placebo, according to research.

Survodutide has an “acceptable safety profile” in patients with metabolic dysfunction-associated steatohepatitis with compensated and decompensated cirrhosis, with no dose reduction needed based on pharmacokinetics, according to data.

New survey results from the AMA illustrate the burden of prior authorization, with many physicians reporting that it leads to serious patient harms, delays care, reduces work productivity and more.